Cognitive Function in IPF

  • Research type

    Research Study

  • Full title

    Investigation into the relationship between stable normoxic Idiopathic Pulmonary Fibrosis and cognitive dysfunction

  • IRAS ID

    167905

  • Contact name

    Charles Sharp

  • Contact email

    charles.sharp@bristol.ac.uk

  • Sponsor organisation

    North Bristol NHS Trust

  • Duration of Study in the UK

    0 years, 12 months, 0 days

  • Research summary

    Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with only one currently approved disease modifying treatment, however there have been recent advances in our understanding which have led to clinical trials examining the safety and efficacy of several promising drugs. It is therefore important to identify and characterise clinically important outcomes for these novel treatments. IPF has been associated with several co-morbidities, including coronary artery disease and venous thromboembolic disease. Cognitive dysfunction is one such clinically important co-morbidity, known to be associated with impaired lung function but has yet to be examined in IPF. This study aims to establish any association between stable normoxaemic patients with IPF and cognitive dysfunction, which may suggest a multi-system disease process, or indicate important disease-related consequences.

  • REC name

    East Midlands - Derby Research Ethics Committee

  • REC reference

    14/EM/1292

  • Date of REC Opinion

    17 Dec 2014

  • REC opinion

    Further Information Favourable Opinion